At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Evaluation of Adjuvant Hyperfractionated Radiation and Docetaxel for HPV Associated Oropharynx Cancer
In Brief
A Phase 2 clinical trial evaluating Docetaxel, Hyperfractionation, and 3 other interventions for Human Papillomavirus Infection and 5 related conditions. Completed, enrolled 81 participants across 2 sites.
Detailed Summary
This phase II trial studies how well radiation therapy and docetaxel work in treating patients with human papillomavirus (HPV)-related oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving radiation therapy with docetaxel my kill more tumor cells.
Study Details
Timeline
Interventions
Given IV
Undergo hyperfractionated IMRT
Undergo hyperfractionated IMRT
Correlative studies
Ancillary studies